Eiko Lifesciences Ltd Q1FY22 PAT at Rs. 40.12 lakhs

Eiko Lifesciences Ltd has reported financial results for the period ended June 30, 2021.

Financial Results (Q1 FY2021-22) - QoQ Comparison

The company has reported total income of Rs.8.57 crores during the period ended June 30, 2021 as compared to Rs.6.28 crores during the period ended March 31, 2021.

The company has posted net profit / (loss) of Rs.0.40 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.0.35 crores for the period ended March 31, 2021.

The company has reported EPS of Rs.0.64 for the period ended June 30, 2021 as compared to Rs.0.93 for the period ended March 31, 2021.

Financials	Q1 FY2021-22	Q4 FY2020-21	% Change
Total Income	₹ 8.57 crs	₹ 6.28 crs	36.46%
Net Profit	₹ 0.40 crs	₹ 0.35 crs	14.29%
EPS	₹ 0.64	₹ 0.93	-31.18%

Financial Results (Q1 FY2021-22) - YoY Comparison

The company has reported total income of Rs.8.57 crores during the period ended June 30, 2021 as compared to Rs.0.10 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.0.40 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.0.0254 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.0.64 for the period ended June 30, 2021 as compared to Rs.0.07 for the period ended June 30, 2020.

Financials	Q1 FY2021-22	Q1 FY2020-21	% Change
Total Income	₹ 8.57 crs	₹ 0.10 crs	8470%
Net Profit	₹ 0.40 crs	₹ 0.0254 crs	1474.8%
EPS	₹ 0.64	₹ 0.07	814.29%

The Paid up Share Capital of the company has increased from Rs. 3.82 Cr to Rs. 8.32 Cr on account of issuance and allotment of 24,29,967 Equity Shares having a face value of Rs. 10/- each, issued for cash at Rs. 30/- per share aggregating to Rs. 7,28,99,010/- and 20,66,300 equity shares having a face value of Rs. 10/- each, issued for consideration other than cash at Rs. 70/- per share aggregating to Rs. 14,46,41,000/-, both on a preferential basis.

Source : Equity Bulls

Keywords